Cleveland HeartLab LLC (CHL), a Cleveland, Ohio-based clinical laboratory and disease management company focused on offering propriety diagnostic tests based on molecular biomarkers, has completed a $3.0m financing round.
CHL’s new shareholders include local business leaders, and Glengary LLC, Second Generation Ltd. and Zapis Capital Group LLC.
In conjunction with the financing, the company also announced that Les C. Vinney was elected as chairman. of the board of directors.
At the same time, Jake Orville was elected CHL’s president and chief executive.
Drs. Marc Penn and Stanley Hazen have been appointed as chief medical officer and chief scientific officer, respectively.
In addition, the advisory board, which will be led by Dr. Penn., will include a group of nationally-recognized experts such as William C. Popik, M.D., Michael C. Fiore, and Melissa A. Ohlson, M.S., R.D., L.D.
The funds will enable CHL to expand its reference laboratory operations, increase selling and marketing efforts, advance the pipeline of markers like dysfunctional HDL and nitrotyrosine, and move towards profitability.